logo

Clementia Pharmaceuticals Inc. (CMTA)



Trade CMTA now with
  Date
  Headline
11/8/2018 8:45:36 AM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.62 From -1.52
11/8/2018 8:45:18 AM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.42 From -0.40
11/7/2018 6:39:22 AM Clementia Pharma Q3 Net Loss $14.8 Mln Or $0.46/Shr Vs $39.0 Mln Or $1.83/Shr Last Year
10/29/2018 9:29:19 PM Clementia Pharma Prices Public Offering Of 5.30 Mln Shares At $13.25/shr
10/2/2018 6:31:25 AM Clementia Initiates Phase 1 Clinical Trial Of Palovarotene Eye Drop Formulation In Healthy Volunteers
9/26/2018 8:35:17 AM Clementia Announces Updated Data From Open Label Extension Of Ongoing Phase 2 Clinical Trial Of Palovarotene
8/16/2018 6:31:57 AM Clementia Reports Completion Of Enrollment In Phase 3 MOVE Trial For FOP
8/10/2018 7:48:01 AM Wedbush Is Increasing Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.52 From -1.89
8/10/2018 7:47:43 AM Wedbush Is Raising Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.40 From -0.52
8/10/2018 7:47:30 AM Wedbush Is Raising Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.38 From -0.49
8/10/2018 7:47:05 AM Wedbush Reiterates Clementia Pharmaceuticals Inc. (CMTA) At Outperform With $26 Price Target
8/9/2018 6:41:01 AM Clementia Pharma Q2 Net Loss $10.8 Mln Or $0.34/Shr Vs Loss $23.3 Mln Or $9.54/Shr Last Year
7/13/2018 6:31:06 AM Clementia Pharma Appoints Steve Forte As CFO, Effective August 3
7/5/2018 6:35:32 AM Clementia Pharma Appoints Industry Executive Shawn Tomasello To Its Board Of Directors
5/24/2018 10:36:58 AM Prevail Therapeutics Appoints Francois Nader To Its Board